Monte Rosa Therapeutics (GLUE) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Monte Rosa Therapeutics (GLUE) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 18.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 92.37% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 2.29 Bn | 1.61 Bn | - | -195.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -195.02% |
| Dec 31, 2025 | -195.95% |
| Sep 30, 2025 | -13.50% |
| Jun 30, 2025 | 59.44% |
| Mar 31, 2025 | 246.58% |
| Dec 31, 2024 | 192.43% |
| Sep 30, 2024 | 31.60% |
| Jun 30, 2024 | 13.84% |
| Mar 31, 2024 | 0.17% |
| Dec 31, 2023 | -8.02% |
| Sep 30, 2023 | -27.70% |
| Jun 30, 2023 | -32.90% |
| Mar 31, 2023 | 50.58% |
| Dec 31, 2022 | 25.22% |
| Sep 30, 2022 | 73.23% |
| Jun 30, 2022 | 74.25% |
| Mar 31, 2022 | -463.48% |
| Dec 31, 2021 | -236.09% |
| Sep 30, 2021 | -1,498.07% |
| Jun 30, 2021 | -1,805.10% |